Overview
Improving Outcomes in CTD-PAH: Diagnosis, Treatment & Multidisciplinary Care
CME Touchpoint
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this interview-style eNewsletter, Dr. Dinesh Khanna and Dr. Victor Tapson share ways to improve the recognition and diagnosis of CTD-PAH. Through discussions on the role of screening and a review of current and emerging therapies, our faculty provide context to creating a personalized treatment approach that highlights the importance of increasing communication across a multidisciplinary team.
This activity is intended for rheumatologists, pulmonologists, cardiopulmonologists, cardiologists, and other clinicians who care for patients at risk for CTD-PAH.
Given the impact on patient outcomes, screening of PAH in CTD patients is of critical importance. The purpose of this activity is to enhance clinician skills in the recognition and diagnosis of CTD-PAH in order to provide effective treatment within a multidisciplinary team. Faculty provide practical guidance on screening tools and effective therapies to enable clinicians to improve patient care.
Upon completion of this activity, participants will be able to:
• Discuss the impact that various screening protocols have on CTD-PAH patient outcomes
• Interpret the efficacy and safety data of traditional PAH pharmacotherapies for treatment of CTD-PAH patients
• Apply a collaborative approach across multidisciplinary experts to effectively diagnose and manage CTD-PAH
• Discuss the impact that various screening protocols have on CTD-PAH patient outcomes
• Interpret the efficacy and safety data of traditional PAH pharmacotherapies for treatment of CTD-PAH patients
• Apply a collaborative approach across multidisciplinary experts to effectively diagnose and manage CTD-PAH
This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL) and Purdue University College of Pharmacy.
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals, and Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Dinesh Khanna, MD, MSc
Director, Scleroderma Program
Professor of Medicine
University of Michigan
Ann Arbor, MI
Director, Scleroderma Program
Professor of Medicine
University of Michigan
Ann Arbor, MI
Victor Tapson, MD
Professor of Medicine, Director Venous Thromboembolism and Pulmonary Vascular Disease Research, Associate Director, Pulmonary/Critical Care
Cedars-Sinai Medical Center
Los Angeles, CA
Purdue University College of Pharmacy requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Dinesh Khanna, MD, MSc
Sources of Funding for Research: Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb; Horizon Therapeutics; Pfizer Inc.
Consulting Agreements: AbbVie Inc; Acceleron; Actelion Pharmaceuticals US, Inc.; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim; Corbus Pharmaceuticals; CSL Behring; Genentech/Roche; GlaxoSmithKline; Horizon Therapeutics; Merck & Co., Inc.; Mitsubishi Tanabe Pharma; Sanofi-Aventis; United Therapeutics
Stockholder: Eicos Sciences, Inc
Victor Tapson, MD
Advisory Board: Actelion Pharmaceuticals US, Inc.; United Therapeutics
Sources of Funding for Research: Actelion Pharmaceuticals US, Inc.; United Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL and Purdue University College of Pharmacy staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
